Details of the Drug Combination

General Information of Drug Combination (ID: DCYV615)

Drug Combination Name

Semaglutide GTx-024

Indication

Disease Entry	Status	REF
Muscle Loss	Phase 2	[1]

Component Drugs

Semaglutide DMAGFOD

GTx-024 DMZXF05

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Semaglutide

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Approved	[2]

Semaglutide Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Glucagon-like peptide 1 receptor (GLP1R)	TTVIMDE	GLP1R_HUMAN	Agonist	[5]
------------------------------------------------------------------------------------

Semaglutide Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Dipeptidyl peptidase IV (DPP4)	DEKZQY6	DPP4_HUMAN	Metabolism	[6]
Neprilysin (MME)	DEVN830	NEP_HUMAN	Metabolism	[6]
------------------------------------------------------------------------------------

Indication(s) of GTx-024

References

1	ClinicalTrials.gov (NCT06282458) Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
2	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3	ClinicalTrials.gov (NCT01355497) Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum. U.S. National Institutes of Health.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
6	Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017 Jun 15;104:31-41.